Loading please wait...
Event Details
Understanding the Application of Real-World Evidence and Comparing Treatment Options in Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
Join Michael Johnson, MD, FACS, and David Morris, MD, FACS, as they discuss the value of real-world evidence and how it can be incorporated into daily practice to support shared decision-making. This webinar will delve into key data from 2 recent head-to-head real-world analyses of androgen receptor pathway inhibitors to explore survival outcomes in metastatic castration-sensitive prostate cancer.
Supporting File
Speaker
David Morris, MD, FACS
David Morris, MD, FACS. President and Co-Director of The Advanced Therapeutics Center at Urology Associates, PC, Nashville, TN Originally from Cleveland in East Tennessee, Dr. Morris attended The Baylor School in Chattanooga, TN. He graduated Summa Cum Laude from Vanderbilt University and then earned his doctorate from Vanderbilt University School of Medicine. Dr. Morris completed his residency training at the University of Michigan in Ann Arbor, MI with a special research interest in genetics that predicts the aggressiveness of prostate and bladder cancers. He authored and co-authored multiple scientific papers throughout his training and has presented research findings at regional and national meetings. Dr. Morris has been practicing urology since 2008. In addition to being Urology Associates’ president, he is the co-director of the Advanced Therapeutics Center for prostate cancer therapies and the Clinical Research Department.
... Show More.jpg?sv=2018-03-28&sr=c&sig=jeW76%2BI5YozaHlBMHq8KsSeq4PxvF1CKarDhqYyhI%2Fc%3D&st=2025-12-07T06%3A07%3A06Z&se=2025-12-07T10%3A12%3A06Z&sp=r)
Michael Johnson, MD, FACS
Dr. Johnson is a Professor, Interim Division Chief, Urology, and Director of the Society for Urologic Oncology Fellowship at Washington University in St. Louis, MO. He has held positions in private practice at Oregon Urology Institute and at the Brady Urological Institute at Johns Hopkins Hospital. Dr. Johnson received his undergraduate degree from Dartmouth College, his medical degree from the University of Washington, his residency at Washington University in St. Louis, MO, and his fellowship in urologic oncology at the Brady Urological Institute at Johns Hopkins Hospital. Dr. Johnson's research experience includes funding from the National Institutes of Health to advance "big data" efforts for precision medicine in kidney cancer and prostate cancer. Dr. Johnson has received numerous awards for his teaching and research efforts. He has authored many scientific publications, including research articles, videos of surgical techniques, and textbook chapters
... Show More
Video
Understanding the Application of Real-World Evidence and Comparing Treatment Options in Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
00:40:10
February 2025 Opening Slides
00:00:30